Bone Marrow Dosimetry in Radioiodine (I-131) Treatment Radyoiyot (I-131) Tedavisinde Kemik İliği Dozimetrisi

Creative Commons License

Parlak Y.

Nuclear Medicine Seminars, cilt.11, sa.1, ss.15-20, 2025 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 11 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.4274/nts.galenos.2025.91300
  • Dergi Adı: Nuclear Medicine Seminars
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier
  • Sayfa Sayıları: ss.15-20
  • Anahtar Kelimeler: bone marrow dosimetry, dosimetry on I-131 treatment, Radioiodine treatment
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

In radioiodine therapies, the most radiosensitive tissue in the body is the red bone marrow. The maximum iodine-131 activity is calculated through dosimetry to ensure that the blood-representing the dose-limiting organ, the bone marrow-receives a dose below 2 Gy during treatment. Dosimetry involves calculations based on measuring blood samples collected from the patient after administering approximately 74 MBq (2 mCi) of radioiodine, using a gamma counter.